anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To develop and validate a nomogram for predicting recurrence-free survival (RFS) for clinical T1/2 (cT1/2) clear cell renal cell carcinoma (ccRCC) patients after nephrectomy.
METHODS: Clinicopathological and survival data from 1289 cT1/2 ccRCC patients treated at the Second Hospital of Tianjin Medical University between 2017 and 2020 were included. Cox regression analysis was used to identify independent risk factors in 902 and 387 ccRCC patients in the training and validation cohorts, respectively, and construct the nomogram. The performance of the nomogram was assessed through calibration plots, time-dependent receiver operating characteristic (ROC) curves, C-index (concordance-index), and decision curve analysis (DCA). Kaplan-Meier curves were used to evaluate the probability of RFS in patients with different recurrence risks.
RESULTS: Age, tumor size, surgical approach, Fuhrman grade, and pT3a upstage were identified as independent predictors of RFS. The area under the curve (AUC) for the 3-year and 5-year RFS ROC curves were 0.791 and 0.835 in the training cohort, and 0.860 and 0.880 in the validation cohort. The DCA and calibration plots demonstrated the optimal application and excellent accuracy of the nomogram for predicting 3-year and 5-year RFS. Kaplan-Meier curves revealed significant differences in RFS among the three risk groups in both the training and validation cohorts. Clinically, the developed nomogram provides a more precise tool for risk stratification, enabling tailored postoperative management and surveillance strategies, ultimately aiming to improve patient outcomes.
CONCLUSIONS: We developed a nomogram for predicting RFS in cT1/2 ccRCC patients after nephrectomy with high accuracy. The clinical implementation of this nomogram can significantly enhance clinical decision-making, leading to improved patient outcomes and optimized resource utilization in the management of ccRCC.
BACKGROUND: Visceral pain accounts for nearly 28% of cancer-related pain, and its effective management poses significant challenges. The diverse pathways of neurotransmission, neurotransmitters, channels, and receptors suggest the need for individualized analgesic therapy. Our objective is to explore a therapeutic alternative for managing malignant visceral pain in advanced cancer.
CASES: In this report, we present two patients with malignant bowel obstruction and severe visceral pain, despite receiving opioid treatment, necessitating an alternative approach. Surgical interventions were considered but promptly ruled out. Paracentesis was performed as necessary. Pain management was initiated using a combination of opioids and co-analgesics. However, both patients required opioid dose escalation without achieving adequate pain control or tolerating the associated side effects. Consequently, a lidocaine infusion was administered to alleviate pain.
OUTCOME: Following 24-48 hours of lidocaine infusion, both patients achieved satisfactory symptom control, enabling a reduction in opioid doses and improvement in intestinal transit. No side effects were reported during the treatment.
DISCUSSION: Lidocaine infusions may be beneficial for pain management in patients with malignant bowel obstruction and visceral pain. The extent of pain control achieved in comparison to other therapeutics remains challenging to ascertain. We posit that lidocaine infusions, with their potential impact on visceral hypersensitivity, can enhance pain control and facilitate the recovery of bowel transit. Further studies are warranted to validate these findings.
FIELD: medicine. ^ SUBSTANCE: present invention refers to a spray drying production process of a solid pharmaceutical powder containing microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer. In a parent mixture, the relation of the water-soluble polymer to TMC 125 makes 10:1 to 1:1, and of microcrystalline cellulose to TMC 125 - 1:1 to 1:3. Said parent mixture of microcrystalline cellulose, a solution of the water-soluble polymer and etravirine is sprayed in the form of drops into a drying chamber by atomisers to form a solid dispersion of TMC 125 powder. ^ EFFECT: better solubility and bioavailability of the antiviral compound etravirine. ^ 10 cl, 9 dwg, 2 tbl, 1 ex
Cigarette smoking among adults living with HIV (ALHIV) is a significant public health problem, leading to substantial morbidity and mortality in this population. Existing smoking cessation interventions are not sufficient, as success rates are relatively low. Poor sleep is more prevalent among smokers, more prevalent among ALHIV, can be caused by smoking cessation attempts, predicts relapse to former smoking patterns, and represents a parallel pathway to morbidity including increased cardiovascular disease (CVD) among ALHIV. Thus, unhealthy sleep may make smoking cessation more difficult and increase cardiovascular risk and other poor health conditions in ALHIV. The proposed study will supplement an empirically-supported smoking cessation program (8-session, 13-week counseling program with varenicline tartrate) with a pre-determined behavioral health approach to reducing smoking intervention developed for smokers. The investigators will test the efficacy of behavioral health approach 1 versus behavioral health approach 2 as an active comparator. The investigators will also explore the impact of smoking cessation and changes in sleep on changes in inflammatory biomarkers of cardiovascular disease risk. Approximately 400 ALHIV treatment seeking smokers who have no history of sleep disorders will be screened (through history, physical examination, laboratory studies and an overnight sleep test) to identify 200 eligible subjects to randomize to Intervention Approach 1 versus Intervention Approach 2. All participants will concurrently receive standard smoking cessation treatment including counseling and 12-weeks of varenicline tartrate. Screening and treatment sessions will take place at the University of Arizona's Clinical and Translational Sciences Research Center, which is well equipped with private examination rooms and phlebotomists. Successful smoking cessation will be assessed at end of therapy (13 weeks) and again 6 months later by self reports, carbon monoxide breath test, and urine and serum cotinine, a stringent objective marker of tobacco use. Sleep will be assessed through sleep diaries, questionnaires and actigraphy (activity sensors worn on the wrist). Other markers of CVD risk including lipids, 24 hour blood pressure monitoring, and HgbA1C, and biomarkers (IL-6, hsCRP, TNFalpha,ICAM-1, VCAM-1, sCD14, D-dimer) will be determined at baseline, end of therapy, and 6 months follow up. Cognitive function will be assessed through N-Back (uses images), Psychomotor Vigilance Test (PVT), Abstract Matching (AM), Digital Symbol Substitution Task (DSST), Visual Object Learning Task (VOLT), Motor Praxis Task (MPT), Balloon Analog Risk Task (BART), and Line Orientation Task (LOT).

Ultimately, the impact of this work will be to transform clinical guidelines for the treatment of nicotine dependence, as well as to provide insights into mechanisms by which improved sleep enhances tobacco cessation.
Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
Idiopathic Pulmonary Fibrosis (IPF) is a disease of aging associated with intense medical and financial burden and expected to grow in incidence within the US population. Median survival from diagnosis is 3.8 years, although some patients succumb to a rapid death within 6 months. New therapies have recently become available. While these medications slow the rate of pulmonary deterioration, they have no impact on ultimate survival or quality of life. Although transplantation is an effective surgical therapy, less than 20% of patients ever receive a lung transplant. The remaining 80% have few treatment options and a likely rapidly progressive downhill course. Despite the fatal prognosis, we have found that patients and caregivers often fail to understand the poor prognosis as the disease relentlessly progresses. At the end of life, IPF patients and their caregivers experience stress, symptom burden, poor quality of life, and inadequate preparedness for end-of-life care planning.

The proposed study will measure feasibility, acceptability, and impact of a Supportive Care intervention. Patients with IPF and their caregivers will be randomized to receive this intervention or usual care. The intervention will include information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, digital (tablet) delivered by an interventionist. The usual care group will be provided with routine printed patient education.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use capable of suppressing crease formation and preventing generation of creases and excellent in improving effects for skin roughness, dandruff, etc. SOLUTION: Tihs skin preparation for external use contains, as an effective ingredient, 0.001-10wt.% of a keratinization inhibition (e.g. 25-hydroxycholesterol) belonging to an oxycholesterol and selected from a sterol having an oxygen- containing substituent except hydroxyl group at 3 position in a cholesterol structure or its derivative structure and 6-nitrocholestelol. Further, one or more of humectants selected from among an amino acid or its derivative and a mucopolysaccharide are blended. The amount to be blended is preferably 0.001-20wt.% of the amino acid or its derivative and 0.001-10wt.% of the mucopolysaccharide.  By using the keratinization inhibitor together with the humectant, a synergistic effect is enhanced and the skin preparation for external use capable of bringing out further enhanced crease improving effects and expanded and moistened skin and having durable moisturizing effect is obtained.
Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
Received Families Talking Together (FTT) intervention, an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative sexual and reproductive health outcomes in adolescents age 10-14. The FTT intervention consisted of two components. Component 1 was comprised of 2 FTT intervention sessions between a parent and bilingual/bicultural promotor trained to deliver FTT in English or Spanish. These sessions highlighted adverse health consequences of sex to motivate parents to communicate with their adolescent and provided guidance to parents on communication strategies. Component 2 was comprised of written supplemental materials that promotores used to guide each intervention session. Experimental condition families will complete all measurement assessments.
The invention relates to a medicinal preparation for treating anorectal diseases and a preparation method and application thereof. The medicinal preparation for treating anorectal diseases is prepared by raw materials such as sodium sulfide, menthol crystal, ethylene diamine tetraacetic acid, ethanol, propylene glycol, purified water and the like. The medicinal preparation for treating anorectal diseases is a quick-acting dry necrosis preparation. The sodium sulfide in the preparation can stimulate local blood capillary to enable the blood capillary to be constricted, so nutrition supply to lesion tissues is cut off and the lesion tissues are dried up, are necrotized and fall off. The medicinal preparation takes effect in anion state, the effect is strong and rapid and the functions of fixing hemorrhoids and relieving pains are obtained. The menthol crystal is pungent and cool and can relieve pains, so pains caused during medication. According to clinical tests and observation, the medicinal preparation has good effects on treating internal hemorrhoids, external hemorrhoids, mixed hemorrhoids, anal fissure and rectal polyp, the product stability is good and toxic side effect is not caused.
In chronic musculoskeletal conditions, the prognosis tends to be more informative than the diagnosis for the future course of the disease. Many studies have identified clusters of patients who seemingly share similar pain trajectories. In a dataset of low back pain (LBP) patients, pain trajectories have been identified, and distinct trajectory types have been defined, making it possible to create pattern recognition software that can classify patients into respective pain trajectories reflecting their condition. It has been suggested that the classification of pain trajectories may create clinically meaningful subgroups of patients in an otherwise heterogeneous population of patients with LBP. A software tool was created that combined the ability to recognise the pain trajectory of patients with a system that could create subgroups of patients based on their characteristics. This tool is primarily meant for researchers to analyse trends in large heterogeneous datasets without large losses of data. Prospective analysis of pain trajectories is not directly helpful for clinicians. However, the tool might aid in the identification of patient characteristics which have predictive capabilities of the most likely trajectory a patient might experience in the future. This will help clinicians to tailor their advice and treatment for a specific patient.
Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Myocardial infarction (MI) is irreversible damage to the myocardial tissue caused by prolonged ischemia/hypoxia, subsequently leading to loss of contractile function and myocardial damage. However, after a perilous period, ischemia-reperfusion (IR) itself causes the generation of oxygen free radicals, disturbance in cation homeostasis, depletion of cellular energy stores, and activation of innate and adaptive immune responses. The present study employed Abatacept (ABT), which is an anti-inflammatory drug, originally used as an antirheumatic response agent. To investigate the cardioprotective potential of ABT, primarily, the dose was optimized in a chemically induced model of myocardial necrosis. Thereafter, ABT optimized the dose of 5 mg/kg s.c. OD was investigated for its cardioprotective potential in a surgical model of myocardial IR injury, where animals (n = 30) were randomized into five groups: Sham, IR-C, Telmi10 + IR (Telmisartan, 10 mg/kg oral OD), ABT5 + IR, ABT perse. ABT and telmisartan were administered for 21 days. On the 21st day, animals were subjected to LAD coronary artery occlusion for 60 min, followed by reperfusion for 45 min. Further, the cardioprotective potential was assessed through hemodynamic parameters, oxidant-antioxidant biochemical enzymatic parameters, cardiac injury, inflammatory markers, histopathological analysis, TUNEL assay, and immunohistochemical evaluation, followed by immunoblotting to explore signaling pathways. The statistics were performed by one-way analysis of variance, followed by the Tukey comparison post hoc tests. Noteworthy, 21 days of ABT pretreatment amended the hemodynamic and ventricular functions in the rat models of MI. The cardioprotective potential of ABT is accompanied by inhibiting MAP kinase signaling and modulating Nrf-2/HO-1 proteins downstream signaling cascade. Overall, the present work bolsters the previously known anti-inflammatory role of ABT in MI and contributes a mechanistic insight and application of clinically approved drugs in averting the activation of inflammatory response.
At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
PURPOSE: To obtain a controlled release system composed of nucleus comprising a soluble active substance, infiltration-active auxiliary and swellable polymeric auxiliary and shell containing a film-forming element, capable of inducing release of the active substance according to zero-order rate process so as to easily control the delay period for the release. CONSTITUTION: This controlled release system is composed of nucleus comprising a soluble active substance and infiltration-active auxiliary (e.g. lactose, fructose, sodium chloride) and a swellable polymeric auxiliary having hydration tendency not higher than those of the above active substance and infiltration-active auxiliary (e.g. polyvinyl alcohol 6-18wt.% in residual acetate content and 20,000-70,000 in average molar mass) and shell comprising a film-forming element such as cellulose acetate, polyvinyl acetate or polyacrylic acid copolymer and a soluble, hydrophilic or hydrophobic plasticizer (e.g. polyethylene glycol 400-20,000 in average molar mass). In this case, the shell has at least one release open pore for the active substance, or porous structure produced by the increase of intranuclear hydrostatic pressure.
Major Depressive Disorder

The safety and effectiveness of Lexapro for the treatment of major depressive disorder have been established in pediatric patients 12 years of age and older. Use of Lexapro for this indication is supported by evidence from adequate and well-controlled studies in adults with additional evidence from an 8-week, flexible-dose, placebo-controlled study that compared Lexapro 10 mg to 20 mg once daily to placebo in pediatric patients 12 to 17 years of age with major depressive disorder [see Clinical Studies (14.1)]. The safety of Lexapro was similar to adult patients with MDD [see Adverse Reactions (6.1)]. 

The safety and effectiveness of Lexapro for the treatment of major depressive disorder have not been established in pediatric patients younger than 12 years of age. In a 24-week, open- label safety study in 118 pediatric patients aged 7 to 11 years who had major depressive disorder, the safety findings were consistent with the known safety and tolerability profile for Lexapro. 

Generalized Anxiety Disorder 

The safety and effectiveness of Lexapro for the treatment of generalized anxiety disorder have been established in pediatric patients 7 years of age and older. Use of Lexapro for this indication is supported by evidence from adequate and well-controlled studies in adults with additional evidence from an 8-week, flexible-dose, placebo-controlled study that compared Lexapro 10 mg to 20 mg once daily to placebo in pediatric patients 7 to 17 years of age with GAD [see Clinical Studies (14.2)]. The safety of Lexapro was similar to adult patients with GAD [see Adverse Reactions (6.1)]. 

The safety and effectiveness of Lexapro for the treatment of generalized anxiety disorder have not been established in pediatric patients younger than 7 years of age.

Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric patients [see Warnings and Precautions (5.1)]. Decreased appetite and weight loss have been observed in association with the use of SSRIs. Consequently, regular monitoring of weight and growth should be performed in children and adolescents treated with an SSRI such as Lexapro. 

Juvenile Animal Toxicity Data

In a juvenile animal study, male and female rats were administered escitalopram at 5, 40, or 80 mg/kg/day by oral gavage from postnatal day (PND) 21 to PND 69. A delay in sexual maturation was observed in both males and females at ≥ 40 mg/kg/day with a No Observed Adverse Effect Level (NOAEL) of 5 mg/kg/day. This NOAEL was associated with plasma AUC levels less than those measured at the maximum recommended dose (MRHD) in pediatrics (20 mg). However, there was no effect on reproductive function. Increased motor activity (both ambulatory and fine movements) was observed in females prior to daily dosing at ≥ 40 mg/kg/day (3.5 times the MRHD based on AUC levels). A reversible disruption of learning and memory function was observed in males at 80 mg/kg/day with a NOAEL of 40 mg/kg/day, which was associated with an AUC level 3.5 times those measured at the MRHD in pediatrics. There was no effect on learning and memory function in treated female rats.
The invention relates to the technical field of biological products for livestock, and particularly discloses a group I8 avian adenovirus strain and application thereof. The group I8 avian adenovirus strain ZMYVAV-8 has a preservation number of CGMCC No. 14297. It has the characteristics of high toxicity yield and good immunogenicity. Can effectively prevent chicken 'inclusion body hepatitis' caused by the avian adenovirus serotype 8, therefore, the invention also provides the application of the avian adenovirus type I strain ZMYTAV-8 in the preparation of the medicament for preventing the inclusion body hepatitis. Furthermore, the invention provides a bivalent inactivated vaccine of avian adenovirus serotype 4 and serotype 8, which is used for preventing pericardial effusion-hepatitis syndrome and inclusion body hepatitis. The vaccine has good immunogenicity, can well prevent poultry diseases caused by adenovirus, such as 'inclusion body hepatitis' and 'pericardial effusion-hepatitis syndrome', and the like which are popular in recent years, has 100 percent of protection rate on local isolates, and simultaneously has high safety, fast antibody generation and stable efficacy.
This is an open-label, dose escalation phase 1b trial to assess the safety and immunogenicity of the candidate ChAdOx1 MERS vaccine in healthy Middle Eastern adult volunteers aged 18-50. The first-in-human trial is now being conducted in Oxford in UK healthy adult volunteers. The vaccine will be administered intramuscularly.

Volunteers will be recruited and vaccinated at the King Abdulaziz Medical City, M-NGHA, Riyadh. There will be 3 study groups and a total of 24 volunteers will be enrolled. Staggered enrolment will apply for the first three volunteers within each group. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be allocated to a study group by selecting eligible volunteers for enrolment in the order in which they were deemed eligible, following screening.
Participants in the non-clinical group were recruited recruited 2012 from schools in the same district and among children of the same average age as the ADHD-group 2012. The non-clinical group did not have any intervention during the follow-up time. Th non-clinical group was re-assessed during 2015.